Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Nasdaq

6 Analysts Have This to Say About Indie Semiconductor

Analysts have provided the following ratings for Indie Semiconductor (NASDAQ:INDI) within the last quarter:

Benzinga

Beyond Air Earnings Preview

Beyond Air (NASDAQ:XAIR) is set to give its latest quarterly earnings report on Thursday, 2022-06-16. Here's what investors need to know before the announcement. Analysts estimate that Beyond Air will report an earnings per share (EPS) of $-0.27.

Benzinga

What 4 Analyst Ratings Have To Say About Pinnacle Finl Partners

Pinnacle Finl Partners (NASDAQ:PNFP) has observed the following analyst ratings within the last quarter:

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2022

Upgrades

Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth $3,600 Today

Moderna (NASDAQ:MRNA) has outperformed the market over the past 10 years by 32.14% on an annualized basis producing an average annual return of 42.94%. Currently, Moderna has a market capitalization of $49.53 billion.

Benzinga

Mid-Morning Market Update: Markets Open Higher; US Retail Sales Drop In May

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Wednesday.

Benzinga

springbig Completes Merger With Tuatara Capital, Starts Trading On NASDAQ

springbig and Tuatara Capital Acquisition Corporation have completed their business combination.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Minerva Surgical Earnings Perspective: Return On Capital Employed

Minerva Surgical (NASDAQ:UTRS) brought in sales totaling $10.94 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 201.08%, resulting in a loss of $10.93 million.

Benzinga

Exagen's Return On Capital Employed Overview

Exagen (NASDAQ:XGN) brought in sales totaling $10.39 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 45.64%, resulting in a loss of $10.27 million.

Benzinga

Cue Health Earnings Perspective: Return On Capital Employed

Pulled from Benzinga Pro data, Cue Health (NASDAQ:HLTH) posted Q1 earnings of $2.80 million, an increase from Q4 of 91.81%. Sales dropped to $179.41 million, a 6.8% decrease between quarters.

Benzinga

Societal CDMO's Return On Capital Employed Overview

Benzinga Pro data, Societal CDMO (NASDAQ:SCTL) reported Q1 sales of $21.20 million. Earnings fell to a loss of $4.26 million, resulting in a 80.91% decrease from last quarter.

Benzinga

Tango Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, Tango Therapeutics (NASDAQ:TNGX) reported Q1 sales of $5.76 million. Earnings fell to a loss of $25.21 million, resulting in a 14.34% decrease from last quarter.

Benzinga

RAPT Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, RAPT Therapeutics (NASDAQ:RAPT) reported Q1 sales of $641.00 thousand. Earnings fell to a loss of $20.47 million, resulting in a 14.16% decrease from last quarter.

Benzinga

Looking Into Priority Tech Holdings's Return On Capital Employed

Priority Tech Holdings (NASDAQ:PRTH) brought in sales totaling $153.24 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 102.36%, resulting in a loss of $333.00 thousand.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Summit Wireless's Return On Capital Employed Overview

Summit Wireless (NASDAQ:WISA) brought in sales totaling $566.00 thousand during Q1 according to data provided by Benzinga Pro. However, earnings decreased 27.21%, resulting in a loss of $3.90 million.

Benzinga

Arhaus's Return On Capital Employed Insights

According to Benzinga Pro, during Q1, Arhaus (NASDAQ:ARHS) earned $16.06 million, a 152.8% increase from the preceding quarter. Arhaus also posted a total of $246.30 million in sales, a 3.39% increase since Q4.

Benzinga

What 4 Analyst Ratings Have To Say About Tilray Brands

Within the last quarter, Tilray Brands (NASDAQ:TLRY) has observed the following analyst ratings:

Benzinga

Where Skyworks Solutions Stands With Analysts

Skyworks Solutions (NASDAQ:SWKS) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Analyst Ratings for Liberty Braves Group

Within the last quarter, Liberty Braves Group (NASDAQ:BATRK) has observed the following analyst ratings:

Benzinga

Alibaba Ropes In Expedia Head As SCMP CEO As It Devotes Former Chief To NFT Spinoff

Alibaba Group Holding Limited's (NASDAQ:BABA) The South China Morning Post (SCMP) roped in Expedia Group, Inc's (NASDAQ:EXPE) Asian head, Catherine So, as its new CEO, Bloomberg reports. So succeeds Gary Liu, who will leave in July to oversee crypto-spinoff Artifacts Lab. The Harvard alumni So, who's also worked at Groupon, Inc (NASDAQ:GRPN), Star TV, and AOL Time Warner,…

Benzinga

Why Robinhood Markets Stock Is Sliding Today

Robinhood Markets Inc (NASDAQ: HOOD) shares are trading lower Wednesday following bearish analyst coverage from Atlantic Equities.

Benzinga

Sono Motors Partners With Logistics Provider Rhenus - Read Why

Sono Group NV (NASDAQ:SEV) has partnered with the Rhenus Group, a logistics service provider, on using smart solar technology in last-mile logistics. The cooperation aims to collect extensive solar data in real-world operations on the road to further optimize the potential of Sono Motors' solar technology for use on vans. A Rhenus…

Benzinga

Where Oatly Group Stands With Analysts

Oatly Group (NASDAQ:OTLY) has observed the following analyst ratings within the last quarter:

Benzinga

Where Cricut Stands With Analysts

Analysts have provided the following ratings for Cricut (NASDAQ:CRCT) within the last quarter:

Benzinga

Kymera Therapeutics Commences Initial-Stage Oncology Trials

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

1 … 427 428 429 430

Organisations

Alibaba Group Holding Limited

South China Morning Post

80 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.